Zymeworks (ZYME) to acquire Theravance Biopharma (TBPH) for $929M / <meta name=

7.00 per share cash + CVR on Monday June 29 — 22% premium to March 3 (Phase 3 CYPRESS-day) close; YUPELRI ($266.6M 2025 US sales) + TRELEGY royalties join ZYME portfolio; ZYME -5.4%, TBPH ~7.01; close H2 2026" /> 7.00 per share cash + CVR on Monday June 29 — 22% premium to March 3 (Phase 3 CYPRESS-day) close; YUPELRI ($266.6M 2025 US sales) + TRELEGY royalties join ZYME portfolio; ZYME -5.4%, TBPH ~7.01; close H2 2026" />

Stock/TLDR — What Just Moved Markets: Earnings, Fed, M&A, MoversA high-volume feed of market-moving releases — quarterly earnings, FOMC decisions, M&A, regulatory actions, big single-name moves, macro prints, commodities and crypto — refreshed every 12 hours. Each release is explained in plain English so you actually understand what just happened and which tickers it touches.This site uses JavaScript to render the interactive feed. Enable JavaScript to use it.Stock/TLDR is not investment advice. Verify everything against primary sources before trading.